Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

oxaliplatin / Generic mfg.

RuCorT-03, NCT04135313: Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer

Enrolling by invitation

540

RoW

Capecitabine, Xeloda, Oxaliplatin, Radiotherapy, Rectal cancer surgery

Blokhin's Russian Cancer Research Center

Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer

10/24

NCT04135781: Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Recruiting

616

RoW

nab paclitaxel, albumin bound paclitaxel, Tegafur, S-1, Oxaliplatin, Capecitabine

Zhejiang Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Stomach Cancer

10/24

TRIPLET-III, NCT05313282: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

Recruiting

140

RoW

Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab

Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.

C-staged Hepatocellular Carcinoma in BCLC Classification

11/24

06/25

NCT05610332: Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

Not yet recruiting

216

RoW

Camrelizumab, Albumin Taxol, FLOT scheme

Fujian Medical University

Locally Advanced Gastric Cancer

11/24

11/27

BREAKWATER, NCT04607421 / 2020-001288-99: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

	Jan 2025 - Dec 2025: Approval for 1L BRAFV600E metastatic CRC (based on BREAKWATER trial)
	Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
	Jan 2023 - Jan 2023: Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023

Recruiting

815

Europe, Canada, Japan, US, RoW

Encorafenib, Braftovi, PF-07263896, LGX818, ONO-7702, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, Irinotecan, Campostar, Leucovorin, Wellcovorin, Fusilev, Khapzory, 5-FU, Fluorouracil, Capecitabine, Xeloda, Bevacizumab, Zirabev

Pfizer, Ono Pharmaceutical Co. Ltd, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company

Neoplasms

01/25

11/26

COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting

120

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration

National Cancer Institute (NCI), NRG Oncology

Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7

11/24

NCT04595864: Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation

Recruiting

RoW

Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU), TAI

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Hepatocellular Carcinoma, Liver Transplantation

11/24

10/26

PHITT, NCT03017326 / 2016-002828-85: Paediatric Hepatic International Tumour Trial

Active, not recruiting

450

Europe, RoW

Cisplatin, Doxorubicin, Carboplatin, 5Fluorouracil, Vincristine, Etoposide, Irinotecan, Gemcitabine, Oxaliplatin, Sorafenib

University of Birmingham, Fundació Institut Germans Trias i Pujol, University Hospital Munich, University Hospital, Bonn, University of Kiel, University Hospital Tuebingen, University of Padova, Ludwig-Maximilians - University of Munich, Medical University of Gdansk, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Motol University Hospital, Prague, Rennes University Hospital, Children's University Hospital, Ireland, University of Oslo, Princess Maxima Center for Pediatric Oncology, Andaluz Health Service, Swiss Pediatric Oncology Group, Gothia Forum - Center for Clinical Trial, The Leeds Teaching Hospitals NHS Trust, Bambino Gesù Hospital and Research Institute, Newcastle University Centre for Cancer, Newcastle, Experimental Cancer Medicine Centres, XenTech, Evry

Hepatoblastoma, Carcinoma, Hepatocellular

08/26

08/27

COPEC, NCT04922853: Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

Recruiting

554

RoW

Capox chemotherapy

West China Hospital, The Third People's Hospital of Chengdu, Chengdu Fifth People's Hospital, Peking Union Medical College, Beijing Cancer Hospital, Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Yunnan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, Sichuan Provincial People's Hospital, Nanchong Central Hospital, Dazhou Central Hospital, Leshan People's Hospital, GeneCast Biotechnology Co., Ltd.

Rectal Cancer, Neoadjuvant Chemotherapy

12/24

12/26

NCT05194878: Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Recruiting

840

RoW

neoadjuvant chemotherapyI, mFOLFOXIR, Colectomy, adjuvant chemotherapy, FOLFOX/CapeOX/Cape

Sun Yat-sen University

Colon Cancer Stage II, Colon Cancer Stage III

12/24

12/26

NCT05866172: HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

Recruiting

264

RoW

HAIC, Zoledronic acid

Sun Yat-sen University

Hepatocellular Carcinoma

12/24

06/25

NeoFOL-R, NCT05529940: Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Not yet recruiting

609

RoW

Folfirinox

Seoul National University Hospital, Seoul St. Mary's Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Gangnam Severance Hospital

Resectable Pancreatic Cancer, Neoadjuvant Chemotherapy, Effects of Chemotherapy

12/24

12/27

NCT05171660: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Recruiting

436

RoW

Sintilimab Injection, bevacizumab, Oxaliplatin, Capecitabine, Control Test, XELOX + Bevacizumab

Second Affiliated Hospital, School of Medicine, Zhejiang University

Colorectal Cancer Stage IV

12/24

06/25

NCT05751850: HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Recruiting

778

RoW

HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine

Jiangsu HengRui Medicine Co., Ltd.

First-line Treatment of Advanced Pancreatic Cancer

12/24

12/25

HARVEST, NCT03500874: Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM

Terminated

RoW

FUDR, Floxuridine, Oxaliplatin, Xaliplatin, Leucovorin, Folinic Acid, 5FU, 5-Fluorouracil, Irinotecan, CPT-11

Sun Yat-sen University

Colorectal Cancer, Liver Metastases, HAI

08/21

NCT04233151: QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Recruiting

590

RoW

QL1203, Placebo, mFOLFOX6 regimen

Qilu Pharmaceutical Co., Ltd.

Metastatic Colorectal Cancer

12/24

07/25

NCT04854668: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting

748

RoW

Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastatic Colorectal Cancer

12/24

12/25

NCT04787354: Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Recruiting

976

RoW

Oxaliplatin, Capecitabine

Hallym University Medical Center

Gastric Cancer

12/24

12/27

NCT05264896: Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Recruiting

110

RoW

5-FU, Leucovorin, Oxaliplatin, Docetaxel, XELOX

Chinese University of Hong Kong

Cancer of Stomach, Adenocarcinoma

12/24

12/27

FOBEAR, NCT04215731: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer

Recruiting

500

RoW

Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, Restaging, Concomitant Chemoradiotherapy, Surgery, Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging), Induction chemotherpay with FOLFOX

Yanhong Deng

Rectal Cancer

02/25

FANTASTIC, NCT04338191: mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer

Recruiting

638

RoW

mFOLFOXIRI adjuvant chemotherapy, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil, mFOLFOX6 adjuvant chemotherapy

Sun Yat-sen University

Colorectal Cancer

02/25

MATTERHORN, NCT04592913 / 2019-001555-40: Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

	Jan 2024 - Dec 2024: Data from MATTERHORN trial for gastric and gastroesophageal Cancer
	Jan 2024 - Dec 2024: Acceptance of regulatory submission for neo-adjuvant/adjuvant gastric (based on MATTERHORN trial)
	Jul 2020 - Dec 2020 : From trial for MDS

Active, not recruiting

958

Europe, Canada, Japan, US, RoW

Durvalumab, FLOT chemotherapy

AstraZeneca

Gastrointestinal Neoplasms, Esophagogastric Junction

10/25

09/27

NCT06049901: Nitazoxanide in Patients With Metastatic Colorectal Cancer

Recruiting

RoW

Nitazoxanide, Nanazoxid

Tanta University

Metastatic Colorectal Cancer

03/25

03/26

NCT04950322: A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Active, not recruiting

737

RoW

SHR-1701、CAPOX, Placebo、CAPOX

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Gastric or Gastroesophageal Junction Cancer

03/25

06/25

NCT04365036: A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Recruiting

207

RoW

Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT)

Sun Yat-sen University

NK/T Cell Lymphoma Nos

04/25

06/25

PRECAM-R, NCT05752136: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Recruiting

108

RoW

Envafolimab

Sir Run Run Shaw Hospital

Rectal Cancer

04/25

12/28

STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

	Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
	Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
	Feb 2023 - Dec 2023: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for 2L+ DLBCL

Recruiting

270

Europe, US, RoW

Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin

Hoffmann-La Roche

Diffuse Large B-cell Lymphoma

04/25

SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL

Recruiting

222

Canada, Japan, US, RoW

Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin

Hoffmann-La Roche

Non-Hodgkin Lymphoma

05/25

11/27

NCT05954078: Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

Recruiting

340

RoW

mFOLFIRINOX adjuvant chemotherapy, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil, mFOLFOX6/XELOX adjuvant chemotherapy

Fudan University

High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation

06/26

06/28

CheckMate 8HW, NCT04008030 / 2018-000040-26: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

	Jan 2024 - Dec 2024: Data readout from P3 CheckMate 8HW trial for 1L+ MSI High CRC
	Jan 2023 - Dec 2023: Submission in Japan in combination with Opdivo for 1L colorectal cancer (based on CHECKMATE 8HW trial)
	Jan 2023 - Dec 2023: Submission in Japan in combination with Yervoy for 1L colorectal cancer (based on CHECKMATE 8HW trial)

Recruiting

831

Europe, Canada, Japan, US, RoW

Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab

Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd

Metastatic Colorectal Cancer

06/25

06/26

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL

Recruiting

350

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

GEMFOX, NCT04167007: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

Recruiting

400

Europe

Gemcitabine, FOLFOX

Assistance Publique - Hôpitaux de Paris

Pancreatic Adenocarcinoma

07/25

NCT05476432: HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Recruiting

300

RoW

HAIC, FOLFOX 2d, FOLFOX 1d

Sun Yat-sen University, Guangzhou No.12 People's Hospital, First People's Hospital of Foshan

Hepatocellular Carcinoma

07/25

10/26

AFFORD, NCT05427669: Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer

Not yet recruiting

340

mFOLFOXIRI, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, mFOLFOX6

Yanhong Deng

Colorectal Cancer

07/25

07/27

NCT04961970: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Recruiting

188

RoW

oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin

Shi Ming

Intrahepatic Cholangiocarcinoma

07/25

NCT05914610: Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Not yet recruiting

100

Envolimab, Fruquintinib, Oxaliplatin, Tegafur

Fujian Medical University

Gastric Cancer

07/25

07/28

JCOG1801, NCT04288999: Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Recruiting

110

Japan

Chemotherapy, CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV, Preoperative radiotherapy, Capecitabine plus radiotherapy, Procedure, Surgery

National Cancer Center Hospital East, Japan Clinical Oncology Group, Japan Agency for Medical Research and Development

Rectal Cancer Recurrent

08/25

10/28

FORTITUDE-101, NCT05052801 / 2021-003461-35: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Active, not recruiting

516

Europe, Canada, Japan, US, RoW

Bemarituzumab, mFOLFOX6, Placebo

Amgen, Zai Lab (China only)

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

08/25

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen Inc., Merck Sharp & Dohme LLC

Colorectal Neoplasms

08/25

04/28

OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting

348

Europe

Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI

Federation Francophone de Cancerologie Digestive

Colorectal Neoplasms

09/25

09/27

NCT03671252: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation

Recruiting

776

RoW

FOLFOXIRI, XELOX, Chemoradiotherapy, TME operation, efficacy evaluation

Sun Yat-sen University

Rectal Cancer

09/25

09/28

NCT06093425: Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Not yet recruiting

950

TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), TST001 and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin and Nivolumab, Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), Placebo and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin

Suzhou Transcenta Therapeutics Co., Ltd.

Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer

10/25

01/26

NCT06097416: Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer

Not yet recruiting

100

Neoadjuvant Chemoradiotherapy, NACRT, Total Neoadjuvant Therapy, TNT

St. James's Hospital, Ireland

Rectal Cancer

10/25

10/30

NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting

702

Europe

Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin

Prof. Dr. med. Claus Rödel

Rectal Cancer Stage III

10/25

10/28

EFFIPEC, NCT04861558 / 2020-005210-18: Efficacy of Hyperthermic Intraperitoneal Chemotherapy

Recruiting

356

Europe

5Fluorouracil, Fluorouracil Accord, Fluorouracil Tevo, Irinotecan, Irinotecan Accord, Irinotecan Actavis, Irinotecan Fresenius Kabi, Oxaliplatin, Oxaliplatin Accord, Oxaliplatin Teva, Oxaliplatin Fresenius Kabi

Uppsala University

Colorectal Cancer, Peritoneal Metastases

12/25

12/29

iMAGINE, NCT04488159: Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer

Not yet recruiting

1638

Europe

Capecitabine, Oxaliplatin, Fluorouracil, Leucovorin, Immunoscore® assay, Physical exercise

Johannes Laengle, MD, PhD

Colon Cancer Stage III

12/25

06/26

LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/)

Jan 2022 - Jan 2022 : Data from LEAP trial in combination with Keytruda for esophageal squamous cell carcinoma at ASCO-GI 2022

Recruiting

862

Europe, Canada, Japan, US, RoW

Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL®

Merck Sharp & Dohme LLC, Eisai Inc.

Metastatic Esophageal Squamous Cell Carcinoma

12/25

NCT05244642: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Recruiting

RoW

Penpulimab, AK105, Investigator's choice of Chemotherapy

Akeso, Beijing Cancer Hospital

Hodgkin Disease Lymphoma

12/25

03/26

BALLAD, NCT04257461: A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Recruiting

Europe

Fluoropyrimidine, Capecitabine, LV5FU2, Oxaliplatin, Xeloda

Belgian Group of Digestive Oncology, Kom Op Tegen Kanker, Cancer Research UK

Small Bowel Adenocarcinoma

12/25

NCT05669092: A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Recruiting

174

RoW

Toripalimab, PD-1inhibitor, CRT, LCRT, SCRT, short-course radiotherapy, XELIRI, Capecitabine and Irinotecan, FOLFRINOX, Irinotecan,Oxaliplatin and 5-FU

Zhejiang Cancer Hospital

Toripalimab, Radiation

12/25

A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting

352

Canada, US

Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer

01/26

11/30

NCT05198609: Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Recruiting

214

RoW

FOLFOX-HAIC, Camrelizumab, Apatinib

Sun Yat-sen University

Hepatocellular Carcinoma

01/26

NCT05701436: Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Recruiting

144

RoW

Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed

Zhujiang Hospital

Liver, Cancer of, Primary Resectable

01/26

03/26

NCT05766605: Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Recruiting

RoW

Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed

Zhujiang Hospital

Hepatocellular Carcinoma Resectable

01/26

NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Recruiting

176

RoW

Experimental drug, CAP, Control Rx, FOLFIRI+BEV

Sun Yat-sen University

Metastatic Microsatellite-stable Colorectal Cancer

01/26

01/27

NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruiting

190

RoW

HX008, Investigator's Choice Chemotherapy

Taizhou Hanzhong biomedical co. LTD

Metastatic Colorectal Cancer

01/26

10/28

RENAISSANCE, NCT02578368 / 2014-002665-30: Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Active, not recruiting

183

Europe

5-Fluorouracil, 5-FU, Leucovorin, calcium folinate, Oxaliplatin, Docetaxel, Trastuzumab, sodium folinate, Surgery

Krankenhaus Nordwest, German Research Foundation, Arbeitsgemeinschaft fur Internistische Onkologie

Gastric Cancer

02/26

PREOPANC-3, NCT04927780: Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Recruiting

378

Europe

Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Oxaliplatin, Resection

Erasmus Medical Center, Dutch Pancreatic Cancer Group, Dutch Cancer Society

Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma

02/26

07/29

LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/)

Active, not recruiting

890

Europe, Canada, Japan, US, RoW

Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU

Merck Sharp & Dohme LLC, Eisai Inc.

Advanced/Metastatic Gastroesophageal Adenocarcinoma

02/26

NCT05263219: DEB-TACE+HAIC vs. HAIC for Large HCC

Recruiting

230

RoW

dTACE-HAIC, HAIC, dTACE-HAIC protocol, Drugs for DEB-TACE and HAIC, HAIC protocol, Drugs for HAIC

Second Affiliated Hospital of Guangzhou Medical University, Hainan General Hospital, Maoming People's Hospital, Zhongshan People's Hospital, Guangdong, China, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan, Jiangmen Central Hospital, First Affiliated Hospital, Sun Yat-Sen University

Unresectable Hepatocellular Carcinoma

02/26

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Recruiting

680

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

03/26

07/28

TOURMALINE, NCT05771480: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Recruiting

140

Europe, Japan, US, RoW

Durvalumab, Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union., Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Background gemcitabine-based chemotherapy Regimen

AstraZeneca

Biliary Tract Cancer

09/25

03/26

GASTRICHIP, NCT01882933: D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma

Active, not recruiting

367

Europe

HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin, Curative gastrectomy

Hospices Civils de Lyon

Gastric Adenocarcinoma

05/26

NCT05236972: PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Recruiting

323

RoW

Sintilimab, Oxaliplatin, capecitabine

Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, West China Hospital

Colorectal Carcinoma

06/26

12/28

TACTIC, NCT05593458: Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1

Recruiting

190

RoW

Oxaliplatin by arterial infusion plus S-1, SOX neoadjuvant, Sintilimab neoadjuvant, gastrectomy plus D2 lymph node dissection, SOX adjuvant, Sequential S-1, Sintilimab adjuvant

Zhejiang University

Locally Advanced Gastric Carcinoma

06/26

12/26

NCT05948072: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Not yet recruiting

250

RoW

mFOLFOX6 + Cetuximab, mFOLFOX 6

Fudan University

Colorectal Cancer, Liver Metastases

07/26

STAR-221, NCT05568095: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Active, not recruiting

1040

Europe, Canada, Japan, US, RoW

Domvanalimab, AB154, Zimberelimab, AB122, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab

Arcus Biosciences, Inc., Gilead Sciences, Taiho Pharmaceutical Co., Ltd.

Advanced Upper Gastrointestinal Tract Adenocarcinoma

05/26

CAREME, NCT05699746: CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD

Not yet recruiting

RoW

Capecitabine tablets, Oxaliplatin

Zhejiang University, GeneCast Biotechnology Co., Ltd.

Colorectal Cancer

09/26

12/26

NCT04460352: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting

1020

Europe, Canada

Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Neoadjuvant chemotherapy, Esophagectomy, Neoadjuvant radiotherapy (arm B), Neoadjuvant Platin-Taxane Regimen (alternative 1), Cisplatin, paclitaxel, Platinum-Fluoropyrimidine Regimens (alternative 2a), Oxaliplatin, calcium folinate, 5-fluorouracil, Platinum-Fluoropyrimidine Regimens (alternative 2b)

Karolinska University Hospital, University of Leipzig, The Swedish Research Council

Esophageal Squamous Cell Carcinoma

09/26

12/31

FORTITUDE-102, NCT05111626 / 2021-003477-61: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer

Recruiting

528

Europe, Canada, Japan, US, RoW

Bemarituzumab, AMG 552, Nivolumab, Chemotherapy, Placebo

Amgen

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

09/26

PERISCOPE II, NCT03348150 / 2015-005695-15: Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.

Recruiting

182

Europe

Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), HIPEC

The Netherlands Cancer Institute, Erasmus Medical Center, UMC Utrecht, University Medical Center Groningen, Catharina Ziekenhuis Eindhoven

Stomach Neoplasm, Peritoneal Carcinomatosis

10/26

10/29

PREVENT, NCT04447352: HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ

Recruiting

200

Europe

5-Fluorouracil, 5-FU, Leucovorin, Calciumfolinat, Oxaliplatin, Docetaxel, Cisplatin

Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

11/26

05/27

MK-3475-C66, NCT05239741: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer

Recruiting

100

RoW

Pembrolizumab, KEYTRUDA®, MK-3475, Oxaliplatin, Leucovorin, 5-fluorouracil, 5-FU, Irinotecan, Bevacizumab, Cetuximab

Merck Sharp & Dohme LLC

Colorectal Neoplasms

11/26

NCT03368651: The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Recruiting

230

RoW

TAI

Sun Yat-sen University

Hepatocellular Carcinoma

11/26

12/28

NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting

540

RoW

Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab

Sun Yat-sen University

Gastric Cancer

12/26

12/28

NORAD01, NCT03875781: Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer

Recruiting

540

Europe

Chemotherapy, Radiochemotherapy

Assistance Publique - Hôpitaux de Paris

Rectal Cancer, Advanced Cancer

12/26

NRG-GI006, NCT03801876: Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Recruiting

300

Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Esophagectomy, excision of the esophagus, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Proton Beam Radiation Therapy, PBRT, Proton Radiation Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, FOLFOX regimen, FOLFOX, CAPOX regimen, CAPE-OX, OxCap, Docetaxel, Taxotere, 5FU, 5-FU, flurouracil, Tolak, Fluoroplex, Efudex, Carac, Adrucil

NRG Oncology, National Cancer Institute (NCI)

Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma

12/26

12/31

NCT03426904: Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

Recruiting

560

RoW

Neoadjuvant FOLFOX, Conventional adjuvant FOLFOX

Kyungpook National University Hospital

Colon Cancer

12/26

12/29

RESONANCE-2 study, ChiCTR1900023293: A prospective multicenter, randomized, controlled phase III study of oxaliplatin combined with S-1(SOX) neoadjuvant chemotherapy for different cycles in patients with locally advanced gastric adenocarcinoma

Not yet recruiting

524

give SOX for 5 cycles before operation ;give SOX for 3 cycles before operation

the first Medical Center of Chinese PLA General Hospital; Chinese PLA General Hospital, self-raising

locally advanced gastric adenocarcinoma

CIRCULATE, NCT04120701: CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II

Recruiting

1980

Europe

mFOLFOX6

Centre Hospitalier Universitaire Dijon

Patients With Resected Stage II Colon Cancer

01/27

01/28

NCT05144854: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active, not recruiting

626

Japan, RoW

ONO-4538, Nivolumab, Opdivo, Ipilimumab, BMS-734016, Yervoy, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium

Ono Pharmaceutical Co. Ltd

Gastric Cancer

02/27

05/27

KEYNOTE 975, NCT04210115 / 2019-002006-51: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Jan 2026 - Dec 2026: Data from KEYNOTE-975 trial for esophageal cancer

Active, not recruiting

700

Europe, Canada, Japan, US, RoW

pembrolizumab, MK-3475, KEYTRUDA®, placebo, Normal saline solution, cisplatin, PLATINOL®, 5-FU, ADRUCIL®, radiotherapy, leucovorin, calcium folinate, folinic acid, levoleucovorin, FUSILEV®, calcium levofolinate, levofolinic acid, oxaliplatin, ELOXATIN®

Merck Sharp & Dohme LLC

Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)

02/27

NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Not yet recruiting

480

RoW

Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin

Shanghai Junshi Bioscience Co., Ltd.

Intrahepatic Cholangiocarcinoma

05/27

NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting

825

Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88

Pancreatic Cancer Action Network

Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

06/27

HAIC, NCT06041477: Concurrently vs Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable HCC

Recruiting

540

RoW

Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Hepatic arterial infusion chemotherapy (HAIC), Concurrent Lenvatinib, Concurrent targeted therapy, Concurrent PD-1 antibody, Concurrent immunotherapy, Sequential Lenvatinib, Sequential targeted therapy, Sequential PD-1 antibody, Sequential immunotherapy

Sun Yat-sen University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan

Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity

07/27

07/30

NCT04997837: Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Recruiting

433

RoW

PD-1 inhibitor, Oxaliplatin, Capecitabine, Tegafur-gimeracil-oteracil potassium, 5-FU, Radiotherapy, Chemotherapy

Fudan University

Gastric Cancer

07/27

10/27

ChiCTR2200062808: A Randomized Control Clinical Trial of FOLFOXIRI versus FOLFOX Neoadjuvant Therapy for High Risk Stage III Colon Cancer

Not yet recruiting

FOLFOXIRI regimen ;FOLFOX regimen

Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, none

colon cancer

NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting

507

Europe

mFOLFOX6, Leucovorin, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Leucovorin, Oxaliplatin, 5-FU, Irinotecan

Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Colorectal Cancer

11/27

11/30

NCT05700448: Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Not yet recruiting

150

Sugemalimab, Placebo, Pegaspargase, Gemcitabine, Oxaliplatin

CStone Pharmaceuticals

Extranodal NK/T-cell Lymphoma

11/27

11/28

TRIGGER, NCT02704520 / 2015-003009-40: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial

Recruiting

441

Europe

High resolution MRI scan, mrTRG assessment

Imperial College London

Rectal Cancer

12/27

12/34

NCT04375605: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Active, not recruiting

342

Europe

5-Fluorouracil, Calcium folinate, Folinic Acid, Oxaliplatin, Docetaxel, Radiation, Oxaliplatin during radiotherapy, 5-Fluorouracil during radiotherapy

Universitätsmedizin Mannheim, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)

Gastroesophageal Junction Adenocarcinoma

12/25

NCT01935778: Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Recruiting

286

RoW

Docetaxel and capecitabine and oxaliplatin, docetaxel/xeloda/oxliplatin, capecitabine and oxaliplatin

Asan Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Inha University Hospital, Hallym University Medical Center

Gastric Cancer, Adjuvant Chemotherapy, XO

06/28

TaLaR-02, NCT05984485: The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer

Recruiting

766

RoW

neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision

Sun Yat-sen University

Rectal Cancer

07/28

CLAUDIA, NCT05534087: Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

Recruiting

236

RoW

mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy

Seoul National University Hospital

Colon Cancer

09/28

09/30

A022102, NCT05677490: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting

382

Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione,, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, Calcium (6S)-Folinate, Calcium Folinate, Oxaliplatin, 1-OHP, Dacotin, Dacplat, ELOXATIN, Irinotecan, Nivolumab, MDX-1106, Opdivo, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biospecimen Collection, Questionnaire Administration

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma

11/28

NCT05314998: Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Not yet recruiting

394

Europe

Oxaliplatin, Irinotecan, Folinic acid, 5-fluorouracil, Gemcitabine, Capecitabine

John Neoptolemos, Molecular Health GmbH, Deutsches Krebsforschungszentrum (DKFZ), Nationales Centrum für Tumorerkrankungen, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Institut für Medizinische Biometrie

Pancreatic Ductal Adenocarcinoma

01/31

09/31

NCT05797077: Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

Recruiting

346

RoW

Colorectal resection surgery., FOLFOX chemotherapy regimen, CapeOx chemotherapy regimen, Capecitabine, 5-FU/LV

Sixth Affiliated Hospital, Sun Yat-sen University

Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related

02/29

02/31

NCT05863195: Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting

408

Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Floxuridine, 2'-Deoxy-5-fluorouridine, 5-Fluoro-2'-deoxyuridine, 5-Fluorodeoxyuridine, 5-Fluorouracil deoxyriboside, 5-FUdR, FDUR, Floxuridin, Fluorodeoxyuridine, Fluorouridine Deoxyribose, Fluoruridine Deoxyribose, FUdR, WR-138720, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Implantation, Intrahepatic Infusion Procedure, HAI, Hepatic Arterial Infusion, Hepatic Artery Infusion, IHI, Intrahepatic Infusion, Irinotecan, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma

06/29

06/34

ENSEMBLE, NCT05646511: Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer

Recruiting

608

Japan

SCRT, Active Comparator & Experimental, CAPOX, Active Comparator, CAPOXIRI, Experimental

National Cancer Center Hospital East, Japan Agency for Medical Research and Development

Locally Advanced Rectal Cancer

12/29

12/30

NCT05797467: Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

Recruiting

366

RoW

FOLFOX chemotherapy regimens, CapeOx regimens, Bevacizumab, Cetuximab

Sixth Affiliated Hospital, Sun Yat-sen University

Colorectal Cancer, Chemotherapy Effect

04/30

04/33



	Diseases Companies Products Productz Mechanisms of Action Sites